Lupin share price
You have to be logged in to add this to Watchlist.- ₹2,116.65(1.53%)March 21, 2025 15:29:00 PM IST
- NSE
- BSE
- Vol : 1.01M (NSE + BSE)Last 20 day avg : 762.44 K
Lupin is trading 1.53% upper at Rs 2,116.65 as compared to its last closing price. Lupin has been trading in the price range of 2,124.00 & 2,085.00. Lupin has given -10.23% in this year & 7.43% in the last 5 days. Lupin has TTM P/E ratio 37.44 as compared to the sector P/E of 29.04.There are 31 analysts who have initiated coverage on Lupin. There are 7 analysts who have given it a strong buy rating & 10 analysts have given it a buy rating. 4 analysts have given the stock a sell rating.The company posted a net profit of 855.16 Crores in its last quarter.Listed peers of Lupin include Torrent Pharmaceuticals (-0.20%), Dr Reddys Laboratories (1.22%), Lupin (1.53%).The Mutual Fund holding in Lupin was at 16.92% in 31 Dec 2024. The MF holding has increased from the last quarter. The FII holding in Lupin was at 22.04% in 31 Dec 2024. The FII holding has increased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Updated on Mar 22, 2025, 04:14 AM UTC
- Dividend YieldLower than industry0.38Annual dividends as a percentage of the stock price.
- P/BHigher than historical values6.74The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/ELower than historical values33.73Price-to-earnings ratio based on trailing 12-month earnings
- BetaMedium volatility0.86Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.20The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is profitable- The company's revenue grew in December quarter by 10.97% from Rs 5767.71 crore to Rs 5197.41 crore, year-on-year
- The company has grown its December quarter profit by 39.48% from Rs 613.12 crore to Rs 855.16 crore, year-on-year
The debt to equity of the company is higher than the industry median- Company can comfortably pay off its interest obligations with its earnings
- R1
- 2,067.12
- R2
- 2,228.03
- R3
- 2,332.07
- S1
- 1,802.17
- S2
- 1,698.13
- S3
- 1,537.22
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Torrent Pharmaceuticals | Bullish | 3,223.50 | -0.20 | 1,09,092.99 | 68.20 | 15.95 | 0.99 | 24.33 |
| Dr Reddys Laboratories | Neutral | 1,201.10 | 1.22 | 1,00,220.40 | 17.96 | 3.5 | 0.67 | 2.12 |
| Lupin | Bullish | 2,116.65 | 1.53 | 96,621.05 | 45.97 | 6.65 | 0.38 | 1.09 |
| Zydus Lifesciences | Neutral | 918.00 | 0.14 | 92,341.50 | 24.19 | 4.65 | 0.33 | 0.13 |
| Abbott India | Neutral | 30,110.00 | -0.23 | 63,981.64 | 53.39 | 17.34 | 1.36 | 0.99 |
- Promoter(s) holding is moderate at 46.95%
- Promoter(s) have decreased the stake in the company in last 12 months
- FIIs are invested in this company
- FIIs holding has increased by 0.54 percentage points from previous quarter
- Mutual Funds holding has increased by 0.03 percentage points from previous quarter
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-02-11 | Quarterly Results & Others |
| 2024-11-07 | Quarterly Results |
| 2024-08-06 | Quarterly Results |
| 2024-05-06 | Audited Results & Final Dividend |
| 2024-02-07 | Quarterly Results |
- IndustryBiotechnology & Drugs
- ISININE326A01037
- BSE Code500257
- NSE CodeLUPIN
Lupin is trading at 2116.65 as on Fri Mar 21 2025 09:59:00. This is 1.53% upper as compared to its previous closing price of 2084.75.
The market capitalization of Lupin is 96621.05 Cr as on Fri Mar 21 2025 09:59:00.
The average broker rating on Lupin is Buy. The breakup of analyst rating is given below -
- 7 analysts have given a strong buy rating
- 10 analysts have given a buy rating
- 10 analysts have given a hold rating
- 4 analysts have given a sell rating
- 0.00 analysts have given a strong sell rating
The 52 wk high for Lupin is 2403.45 whereas the 52 wk low is 1493.75
Lupin can be analyzed on the following key metrics -
- TTM P/E: 37.44
- Sector P/E: 29.04
- Dividend Yield: 0.38%
- D/E ratio: -
Lupin reported a net profit of 1914.48 Cr in 2024.
The Mutual Fund Shareholding was 16.92% at the end of 31 Dec 2024.